Results 111 to 120 of about 7,686 (201)

Determinants of circulating PCSK9 levels and the efficacy of PCSK9 inhibitor therapies in chronic kidney disease: a systematic review. [PDF]

Eur J Clin Pharmacol
Ábel T, Benczúr B, Csajbókné ÉC.
europepmc   +1 more source

VESALIUS keeps revolutionizing medicine: the case of evolocumab in primary prevention. [PDF]

Eur Heart J Cardiovasc Pharmacother
Galli M, Sciarretta S, Crea F.
europepmc   +1 more source

Evolocumab-induced allergic reaction in a post-partial gastrectomy patient: A case report. [PDF]

Medicine (Baltimore)
Hong X, Jiang X, Xu X, Xiong F, Huang X.
europepmc   +1 more source

Statin Intolerance, Evolocumab for Hyperlipidemia, and Arrhythmia: Lessons Learnt From a Challenging Clinical Scenario. [PDF]

Cureus
Balocco MM, Uddin R, Dimeo SP, Falluji N, Waheed A.   +4 more
europepmc   +1 more source

Fair pricing, fair access; a systematic review of cost-effectiveness of new hyperlipidemia injectable medication in developing countries. [PDF]

Cost Eff Resour Alloc
Azari S, Pourasghari H, Rezaei MA, Behzadifar M, Salehbeigi S, Rajaei S, Jafarzadeh D, Soleimanpour S, Tajdini M.   +8 more
europepmc   +1 more source

Relative Efficacy of Alirocumab, Evolocumab, Inclisiran, and Bempedoic Acid on Lipids in Patients with Cardiovascular Disease or Familial Hypercholesterolaemia. [PDF]

J Clin Med
Khattak S, Ochoa-Ferraro A, Khan N, George S, Khan SQ, Townend JN, Dawson C, Thomas MR.   +7 more
europepmc   +1 more source

Severe angioedema requiring airway intervention following evolocumab administration: a case report. [PDF]

Am J Cardiovasc Dis
Mojahedi A, Friedman A, Idries I, Farid M, Ghannam M, Chadow H.   +5 more
europepmc   +1 more source

PCSK9 Inhibitors for LDL Lowering [PDF]

, 2015
Walsh, James P.
core   +1 more source

Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes - exploratory analysis of the EMSIACS trial. [PDF]

Sci Rep
Jing A, Wang J, Zhang M, Liang Y, Liu J, Zhang N, Wang J, Li X, Li C, Cui Z, Liu Y, Gao J.   +11 more
europepmc   +1 more source

Cost-utility analysis of PCSK9 inhibitors for hypercholesterolemia: a Chinese healthcare perspective. [PDF]

Front Pharmacol
Hu D, Deng X, Feng M, Zhang X, He Q, Wang T, Feng Z.   +6 more
europepmc   +1 more source